| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1050: Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over |
|
Medicine details |
|
| Medicine name | fenfluramine (Fintepla®) |
| Formulation | 2.2 mg/ml oral solution |
| Reference number | 4296 |
| Indication | For the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older |
| Company | UCB Pharma Limited |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/03/2024 |
| NICE guidance | |